Texas Man Charged After Fatal Tesla Full Self-Driving Crash in Katy 
Kawasaki Heavy Shares Slide on Report of ¥200 Billion Capital Raise Plan 
Tesla Q2 Deliveries Lift Chinese Auto Suppliers as EV Demand Improves 
Norway Offshore Oil Workers Reach Wage Deal, Averting Strike 
Switch Seeks $2 Billion Funding at Nearly $50 Billion Valuation Ahead of Potential IPO 
Kioxia Bets on AI Memory Boom With Next-Gen NAND Production in Japan 
Suncorp Cuts 2026 Premium Growth Forecast as Australia, New Zealand Markets Weaken 
BHP Workers Approve New Labour Agreement at WA Iron Ore Operations 
Trump Administration to Launch Voluntary AI Standards for Frontier Models 
Apple Eyes Chinese Memory Chips as AI Shortage Pressures iPhone Supply Chain 
SoftBank’s LY Corp, Bain Raise Kakaku.com Bid to ¥670 Billion, Intensifying Takeover Battle 
Anthropic Tightens AI Access Controls After Reports of China-Based Workarounds 
Northern Star Appoints New CEO as Activist Elliott Pushes for Leadership Overhaul 
Kuaishou Stock Jumps as Kling AI Secures $2 Billion Funding Round 
OpenAI Proposes 5% U.S. Government Stake Amid AI Policy Talks 
EU Chip Industry Faces Growing Risks From China Export Controls and U.S. Technology Dependence: Report 
South Korea will invest 520 billion won in biotechnology next year to boost its development of treatment and vaccines for COVID-19.
The Ministry of Science and ICT said the figure represents a 24.9 percent hike from 2020.
Of that amount, 31.7 billion won will go to COVID-19 treatment and vaccine development and 10.2 billion won for technology to respond to new infectious diseases.
Some of it will also go to research into new core biotech industries, such as 71 billion won to develop a new medicine, 61.8 billion won in medical devices, and 31.1 billion won in regenerative medicine to strengthen research in stem cell technology and others.
The medical devices to be developed targets the elderly and the disabled.
The ministry said it also plans to invest 51.3 billion won to acquire next-generation biotech, such as single-cell analysis.
Last month, 36 South Korean biotech and pharmaceutical companies announced that they invest a combined 10 trillion won by 2023 to hone their competitiveness and technological capabilities.
The firms include Samsung Biologics Co. and Celltrion Inc., will
The government intends to spend a total of 2.2 trillion won on developing new medicine until 2030.
